DIAGNOS Inc. DGNOF
Set alert
0.25 USD -0.01 -2.27%
As of Nov 2, 1:17 PM ET
0.2494 Day range 0.2589
0.13 52-week range 0.38
- YTD
- -4.08%
- 1 year
- -0.24%
- Open
- 0.25
- Prev close
- 0.2552
- Mkt cap
- 30.19M
- Vol
- 45.00K
- Avg vol
- 97.77K
- EPS
- -0.03
- P/E
- 0.00
More statistics
- Low
- 0.2494
- High
- 0.2589
YTD chart
Signals (37)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Oct 30, 2026 | 3 days ago |
| RSI: Oversold | Oct 22, 2026 | 1 week ago |
| RSI: Oversold | Oct 16, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 13, 2026 | 2 weeks ago |
| MACD: Sell Signal | Sep 8, 2026 | 1 month ago |
| RSI: Overbought | Aug 24, 2026 | 2 months ago |
| RSI: Overbought | Aug 7, 2026 | 2 months ago |
| RSI: Overbought | Aug 3, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 29, 2026 | 3 months ago |
| SMA: Bullish | Jul 28, 2026 | 3 months ago |
| SMA: Bearish | Jul 27, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 16, 2026 | 3 months ago |
| RSI: Overbought | Jun 30, 2026 | 4 months ago |
| SMA: Bullish | Jun 25, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 18, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 10, 2026 | 4 months ago |
| MACD: Buy Signal | May 26, 2026 | 5 months ago |
| MACD: Sell Signal | May 22, 2026 | 5 months ago |
| MACD: Buy Signal | May 21, 2026 | 5 months ago |
| RSI: Oversold | May 7, 2026 | 5 months ago |
Newest 20 of 37.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 21, 2024 | Sep 1, 2024 | 0.00 | -0.01 | — | — |
| Aug 21, 2024 | Jun 1, 2024 | 0.00 | -0.01 | — | — |
| Jul 17, 2024 | Mar 1, 2024 | 0.00 | -0.01 | — | — |
| Feb 28, 2024 | Dec 1, 2023 | 0.00 | -0.01 | — | — |
| Nov 28, 2023 | Sep 1, 2023 | 0.00 | -0.01 | — | — |
| Aug 24, 2023 | Jun 1, 2023 | 0.00 | -0.01 | — | — |
News
- DIAGNOS Provides an Update on Stock Warrants
- DIAGNOS Advances Regulatory Strategy with US FDA Submission for CARA System
- DIAGNOS to Hold its Annual General Meeting of Shareholders on September 30, 2026
- DIAGNOS Receives Saudi FDA Medical Device License for CARA System, Bringing AI-Assisted Retinal Image Analysis to Saudi Arabia
- DIAGNOS Receives Health Canada Medical Device Licence for CARA System, Bringing AI-Assisted Retinal Image Analysis to Canadian Optometrists
- DIAGNOS to Extend the Exercise Period of Stock Warrants
- Emerging Growth Research Releases Flash Report on DIAGNOS, Highlighting Regulatory Catalysts and Commercialization Potential for CARA AI Platform
- DIAGNOS to Present at the Emerging Growth Conference on June 10, 2026
- DIAGNOS Announces Amendment to Convertible Debentures
- DIAGNOS Provides an Update on Sales and Regulatory Activities for CARA
Your note
Sign in to keep a note on DGNOF — it syncs with the Stock Master app.